ClinicalTrials.Veeva

Menu

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)

Pfizer logo

Pfizer

Status

Completed

Conditions

Post Menopausal Women With Early Breast Cancer

Treatments

Drug: Aromasin (exemestane)

Study type

Observational

Funder types

Industry

Identifiers

NCT01050634
A5991079

Details and patient eligibility

About

Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire.

Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).

Deeper knowledge of Adverse Events during routine administration.

Enrollment

980 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Early Breast Cancer, post-menopausal, 2-3 yrs adjuvant tamoxifen therapy.

Exclusion criteria

  • Not applicable.

Trial design

980 participants in 1 patient group

Observational
Treatment:
Drug: Aromasin (exemestane)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems